2012 Press Releases

2014 | 2013 | 2012 | 2011 | 2010
Keyword Search
 
DateTitle 
11/20/12Urologix Announces Leadership Change
MINNEAPOLIS, Nov. 20, 2012 (GLOBE NEWSWIRE) -- Urologix®, Inc. (ULGX), the leading provider of in-office procedures for the safe, durable and effective treatment of BPH, today announced a leadership change. The company's Chief Operating Officer Greg Fluet will become interim CEO following the decision of Stryker Warren jr. to retire as CEO and a member of the Company's Board of Directors effective November 30, 2012. Mr. Fluet joined the Company as its Executive Vice President and Chief Opera... 
Printer Friendly Version
11/14/12Urologix Reports Fiscal Year 2013 First Quarter Results and Revises Annual Guidance
First quarter revenue of $4.0 million, up 26.3% year-over-year Cash balance increases to $5.3 million after completion of follow-on offering Cooled ThermoTherapy reimbursement code supported in Medicare review The Company revises fiscal year 2013 total revenue guidance range to $16.0 million to $17.0 million MINNEAPOLIS, Nov. 14, 2012 (GLOBE NEWSWIRE) -- Urologix®, Inc. (Nasdaq:ULGX), the leading provider of in-office procedures for the safe, durable and effective ... 
Printer Friendly Version
11/08/12Urologix to Host Its Fiscal Year 2013 First Quarter Conference Call
MINNEAPOLIS--(BUSINESS WIRE)--Nov. 8, 2012-- Urologix®, Inc. (Nasdaq: ULGX) will host a conference call to present fiscal year 2013 first quarter results on Wednesday, November 14, 2012 at 4:00 p.m. CT, following the Company’s post-market press release on the same day. On the day of the call, please dial 1-866-202-1971 and enter the Participant Passcode 75425848 at least 10 minutes prior to the call. The conference call will be broadcast live ... 
Printer Friendly Version
08/23/12Urologix Reports Results for Fourth Quarter and Fiscal Year 2012
Fiscal year 2012 revenue increased 35% over the fiscal year 2011 period in line with annual guidance Fourth quarter revenue of $4.5 million up 54% year-over-year and down 5% sequentially Positive cash flow in the fourth quarter of $42,000 Completion of secondary offering on August 7, 2012 raised $3.8 million MINNEAPOLIS, Aug. 23, 2012 (GLOBE NEWSWIRE) -- Urologix®, Inc. (Nasdaq:ULGX), the leading provider of in-office procedures for the safe, durable and effective ... 
Printer Friendly Version
08/17/12Urologix to Host Its Fiscal Year 2012 and Fourth Quarter Conference Call
MINNEAPOLIS--(BUSINESS WIRE)--Aug. 17, 2012-- Urologix®, Inc. (Nasdaq: ULGX) will host a conference call to present fiscal year 2012 and fourth quarter results on Thursday, August 23, 2012 at 4:00 p.m. CT, following the Company’s post-market press release on the same day. On the day of the call, please dial 1-866-800-8651 and enter the Participant Passcode 49658187 at least 10 minutes prior to the call. The conference call will be broadcast live ... 
Printer Friendly Version
08/07/12Urologix Announces Closing of Over-Allotment Option
MINNEAPOLIS, Aug. 7, 2012 (GLOBE NEWSWIRE) -- Urologix®, Inc. (Nasdaq:ULGX), the leading provider of in-office procedures for the safe, durable and effective treatment of BPH, today announced the sale of an additional 780,000 shares of its common stock at a price to the public of $0.75 per share. The sale was pursuant to a 45-day over-allotment option granted to the underwriter as part of the Company's recently completed public offering of 5,200,000 shares of its common stock that closed July 5,... 
Printer Friendly Version
07/18/12Urologix Regains NASDAQ Compliance With Minimum Shareholders' Equity Requirement
MINNEAPOLIS, July 18, 2012 (GLOBE NEWSWIRE) -- Urologix®, Inc. (Nasdaq:ULGX), the leading provider of in-office procedures for the safe, durable and effective treatment of BPH, announced today it has received a letter of determination from The Nasdaq Stock Market ("NASDAQ") confirming that the Company has regained compliance with Listing Rule 5550(b)(1) requiring a minimum shareholders' equity of $2.5 million. The determination was received from NASDAQ after the Company reported the completion o... 
Printer Friendly Version
07/05/12Urologix Announces Closing of Follow-On Offering
MINNEAPOLIS, July 5, 2012 (GLOBE NEWSWIRE) -- Urologix®, Inc. (Nasdaq:ULGX), the leading provider of in-office procedures for the safe, durable and effective treatment of BPH, today announced the closing of its previously announced follow-on firm commitment underwritten public offering of 5,200,000 shares of its common stock at a public offering price of $0.75 per share. The Company received approximately $3.2 million in net proceeds from the offering, after deducting underwriting discounts ... 
Printer Friendly Version
06/29/12Urologix Announces Pricing of Follow-On Offering of 5,200,000 Shares of Common Stock
MINNEAPOLIS, June 29, 2012 (GLOBE NEWSWIRE) -- Urologix®, Inc. (Nasdaq:ULGX), the leading provider of in-office procedures for the safe, durable and effective treatment of BPH, today announced the pricing of its registered follow-on firm commitment underwritten public offering of 5,200,000 shares of its common stock at a public offering price of $0.75 per share. The public offering is expected to close on or about July 5, 2012, subject to customary closing conditions. In addition, the Company ha... 
Printer Friendly Version
05/14/12Urologix Announces Three Events at the 107th Annual Meeting of the American Urological Association
Sponsor of Expert Panel Lecture on In-Office BPH Therapies, Moderated by Dr. Claus Roehrborn Presentation of Cooled ThermoTherapy™ (CTT) Clinical Outcomes for Improving Nocturia by Dr. Lori Lerner Exhibitor and Sponsor of a Skills Enhancement Workshop on Advancements in BPH In-Office Therapies MINNEAPOLIS, May 14, 2012 (GLOBE NEWSWIRE) -- Urologix®, Inc. (Nasdaq:ULGX), the market leading medical device company for BPH in-office procedures, announced scheduled participation ... 
Printer Friendly Version
04/26/12Urologix Reports 59% Increase in Revenue Year-Over-Year for Fiscal 2012 Third Quarter
$4.7 million in total revenue, up 2% sequentially Positive cash flow in the quarter of $285 thousand Full year 2012 revenue guidance between $17.0 to $17.5 million MINNEAPOLIS, April 26, 2012 (GLOBE NEWSWIRE) -- Urologix®, Inc. (Nasdaq:ULGX), the leading provider of in-office procedures for the safe, durable and effective treatment of BPH, today reported financial results for its fiscal third quarter ended March 31, 2012. Third quarter fiscal year 2012 revenue totaled $4.7 million, up ... 
Printer Friendly Version
04/20/12Urologix to Host Its Fiscal Year 2012 Third Quarter Conference Call
MINNEAPOLIS, Apr 20, 2012 (BUSINESS WIRE) --Urologix(R), Inc. (Nasdaq:ULGX) will host a conference call to present fiscal year 2012 third quarter results on Thursday, April 26, 2012 at 4:00 p.m. CT, following the Company's post-market press release on the same day. On the day of the call, please dial 1-866-783-2137 and enter the Participant Passcode 31215645 at least 10 minutes prior to the call. The conference call will be broadcast live over the Internet... 
Printer Friendly Version
01/24/12Urologix Reports 48% Increase in Sequential Revenue for Fiscal 2012 Second Quarter
$4.7 million in revenue, 40% quarterly revenue growth year over year Positive cash flow in the quarter of $17 thousand $2 million credit facility established MINNEAPOLIS, Jan. 24, 2012 (GLOBE NEWSWIRE) -- Urologix®, Inc. (Nasdaq:ULGX), the leading provider of in-office procedures for the safe, durable and effective treatment of BPH, today reported financial results for its fiscal second quarter ended December 31, 2011. Second quarter fiscal year 2012 revenue totaled $4.7 million. The 48%... 
Printer Friendly Version
01/18/12Urologix to Host Its Fiscal Year 2012 Second Quarter Conference Call
MINNEAPOLIS--(BUSINESS WIRE)--Jan. 18, 2012-- Urologix®, Inc. (Nasdaq:ULGX) will host a conference call to present fiscal year 2012 second quarter results on Tuesday, January 24, 2012 at 4:00 p.m. CT, following the Company’s post-market press release on the same day. On the day of the call, please dial 1-866-510-0711 and enter the Participant Passcode 86583253 at least 10 minutes prior to the call. The conference call will be broadcast live over the ... 
Printer Friendly Version
01/12/12Urologix Secures $2 Million Credit Facility
MINNEAPOLIS, Jan. 12, 2012 (GLOBE NEWSWIRE) -- Urologix, Inc. (Nasdaq:ULGX), the market leading medical device company for in-office procedures to treat BPH that provide safe, durable and effective results, today announced that it has secured a $2 million credit facility through Silicon Valley Bank ("SVB"), the commercial banking division of SVB Financial Group. "By securing this line of credit, we gain access to additional funds to support the ongoing integration of Prostiva RF Therapy and ... 
Printer Friendly Version
01/06/12Urologix Regains Nasdaq Minimum Bid Price Requirement
MINNEAPOLIS, Jan. 6, 2012 (GLOBE NEWSWIRE) -- Urologix, Inc. (Nasdaq:ULGX) is the market leading medical device company for in-office procedures to treat BPH that provide safe, durable and effective results. Urologix provides urologist customers two proven technologies to treat the widest range of patients suffering from enlarged prostate in the comfort of their office setting, Cooled ThermoTherapy™ (CTT) and Prostiva® RF Therapy. Today, the Company announced that it received a letter, dated... 
Printer Friendly Version
Receive E-mail AlertsE-mail Alert Icon
Sign up to receive e-mail alerts whenever Urologix, Inc. has a press release. Just enter your e-mail address and click Submit.